Transitional cell carcinoma of the corpus uteri

Transitional cell carcinoma of the corpus uteri is an extremely rare malignant neoplasm arising from the endometrium (the lining of the uterus or womb). This tumor is characterized by cells that histologically resemble transitional epithelium, similar to the type of cells that line the urinary bladder, but occurring within the uterine body. It is classified among the rare epithelial tumors of the uterine corpus and is distinct from the more common endometrioid adenocarcinoma. The tumor primarily affects the female reproductive system, specifically the uterine body (corpus uteri). Clinical presentation typically includes abnormal uterine bleeding, which is the most common symptom prompting evaluation. Patients may also experience pelvic pain, abnormal vaginal discharge, or symptoms related to an enlarging uterine mass. The disease predominantly affects postmenopausal women. Diagnosis is established through histopathological examination of endometrial biopsy or hysterectomy specimens, which reveals the characteristic transitional cell morphology. Due to the extreme rarity of this tumor, there are no standardized treatment guidelines specific to transitional cell carcinoma of the corpus uteri. Management generally follows principles used for other uterine carcinomas and typically involves surgical treatment, primarily total hysterectomy with bilateral salpingo-oophorectomy, often accompanied by surgical staging. Adjuvant therapy, including chemotherapy and/or radiation therapy, may be considered depending on the stage at diagnosis and other pathological features. Prognosis varies depending on the stage at presentation, though the limited number of reported cases makes definitive prognostic assessment difficult.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Transitional cell carcinoma of the corpus uteri